Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent steps he has taken mitigate the impact of shortages of (a) Ozempic, (b) Rybelsus, (c) Trulicity, (d) Victoza, (e) Saxenda, (f) Byetta and (g) Bydureon.

We are aware of a supply issue with GLP-1 RA medicines. This includes Ozempic, Rybelsus, Trulicity, Victoza, Saxenda, Byetta and Bydureon. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.

Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.

The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.

We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine while there are shortages and are keeping this under review as the situation evolves.